ClinicalTrials.gg
CompletedNCT01704755TURQUOISE-IIUpdated Jul 12, 2021Results posted

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

A Phase 3 interventional study of ABT-450/r/ABT-267, ABT-333 and Ribavirin (RBV) in Chronic Hepatitis C Infection and Compensated Cirrhosis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-07-12.

Primary conditionHepatitis C, ChronicRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis C, Chronic
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Hepatitis C, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing paritaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. paritaprevir · Hepatitis C, Chronic.

Enrollment
3rd of 16
381 · median 124
Started
2012
with 3 others
Phase 3
9 of 16
none open now
Registered
3rd of 16
by date
Lead sponsor
4 of 16
AbbVie (prior sponsor, Abbott)

Among the 16 studies testing paritaprevir in Hepatitis C, Chronic, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 3rd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 16 studies testing paritaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

Where they have run

About paritaprevir

paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing paritaprevir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis.

Read the detailed description

During the treatment period of the study, participants received treatment with ABT-450/ritonavir/ABT-267 and ABT-333 coadministered with RBV for either 12 or 24 weeks. Upon completing the treatment period or premature discontinuation of the treatment period, participants entered a 48-week post-treatment period.

03

Conditions studied

  • Chronic Hepatitis C Infection
  • Compensated Cirrhosis

Browse trials for

Keywords

  • Cirrhosis
  • Hepatitis C
  • Child Pugh A
  • Compensated Cirrhosis
  • Hepatitis C Genotype 1
  • Cirrhotic
  • Chronic Hepatitis C
  • Hepatitis C Virus
  • ombitasvir
  • paritaprevir
  • dasabuvir
  • Interferon-Free
  • Viekira Pak
04

In context

Hepatitis C, Chronic Reclassified

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

This study's enrollment of 381 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.

Browse Hepatitis C, Chronic studies →

Lead sponsor

AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.

Compared within Hepatitis C, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be practicing specific forms of on study treatment, or be for more than 2 years or surgically sterile
  • Male or female between 18 and 70 years, inclusive, at time of Screening.
  • Chronic -infection prior to study enrollment.
  • Screening laboratory result indicating HCV genotype 1-infection.
  • Compensated cirrhosis defined as a Score of less than or equal to 6 at Screening
  • Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening.

Exclusion criteria

Exclusion Criteria:

  • Significant liver disease with any cause other than as the primary cause
  • Positive test result for surface antigen (HBsAg) or anti- antibody (HIV Ab) at screening.
  • Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir and boceprevir.
  • Any current or past clinical evidence of B or C Classification or clinical history of liver decompensation including ascites (noted on physical exam), variceal bleeding or hepatic encephalopathy.
  • A positive screening ultrasound for hepatocellular carcinoma (HCC) confirmed with a subsequent CT Scan or MRI during the screening period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
381 participants (actual)

Study arms

  • Experimental
    ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks

    ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks

    Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin (RBV)

  • Experimental
    ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks

    ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks

    Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin (RBV)

Interventions

  • DrugABT-450/r/ABT-267, ABT-333

    Drug pages: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir

    Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet

    Also known as: Viekira Pak; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; ABT-333 also known as dasabuvir

  • Capsule

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of study drug

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm

    A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (\< LLOQ) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last actual dose of study drug

  2. Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period

    Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation \[≥ LLOQ\] after HCV RNA \< LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA \[2 consecutive HCV RNA measurements \> 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline\] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks \[≥ 36 days\] of treatment).

    Time frame: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24

  3. Percentage of Participants With Virologic Relapse After Treatment

    Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.

    Time frame: within 12 weeks after the last dose of study drug

08

Results

Posted Jan 6, 2015

Participant flow

Participant flow — Overall Study
MilestoneABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks
Started208172
Completed study drug204163
Completed196165
Not completed127
Withdrew: Adverse event41
Withdrew: Lost to follow-up34
Withdrew: Withdrew consent11
Withdrew: Other (not specified)31
Withdrew: Withdrew consent and personal issues10

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment
Percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment91.896.5
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks · Percentage of participants: 91.8 · 97.5% CI 87.6 to 96.1
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks · Percentage of participants: 91.8 · 97.5% CI 87.6 to 96.1
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks · Percentage of participants: 96.5 · 97.5% CI 93.4 to 99.7
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks · Percentage of participants: 96.5 · 97.5% CI 93.4 to 99.7
SecondaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm

A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (\< LLOQ) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm
Percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm91.896.5
Statistical analysis
  • ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks vs ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks · Regression, Logistic · p = 0.051
SecondaryPercentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period

Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation \[≥ LLOQ\] after HCV RNA \< LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA \[2 consecutive HCV RNA measurements \> 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline\] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks \[≥ 36 days\] of treatment).

Time frame:
Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period
Percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks
Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period0.5 (0.0 to 1.4)1.7 (0.0 to 3.7)
SecondaryPercentage of Participants With Virologic Relapse After Treatment

Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.

Time frame:
within 12 weeks after the last dose of study drug
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Relapse After Treatment
Percentage of participantsABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks
Percentage of Participants With Virologic Relapse After Treatment5.9 (2.7 to 9.2)0.6 (0.0 to 1.8)

Adverse events

Collected over Adverse events were collected from the time of study drug administration until 30 days after the last dose, 16 weeks for the 12-week treatment group and 28 weeks for the 24-week treatment group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks—13/208 (6.3%)175/208 (84.1%)
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks—7/172 (4.1%)146/172 (84.9%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks
ANAEMIABlood and lymphatic system disorders1/2081/172
HAEMATEMESISGastrointestinal disorders0/2081/172
MELAENAGastrointestinal disorders0/2081/172
OESOPHAGEAL VARICES HAEMORRHAGEGastrointestinal disorders0/2081/172
CELLULITISInfections and infestations0/2081/172
FALLInjury, poisoning and procedural complications0/2081/172
HEAD INJURYInjury, poisoning and procedural complications0/2081/172
BLOOD GLUCOSE INCREASEDInvestigations0/2081/172
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/2081/172
HEPATOCELLULAR CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2081/172
Most frequent other events
Showing 10 of 32
Most frequent other events
EventABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks
FATIGUEGeneral disorders68/20880/172
HEADACHENervous system disorders58/20853/172
NAUSEAGastrointestinal disorders36/20835/172
PRURITUSSkin and subcutaneous tissue disorders38/20833/172
INSOMNIAPsychiatric disorders32/20831/172
DIARRHOEAGastrointestinal disorders30/20829/172
RASHSkin and subcutaneous tissue disorders23/20825/172
ASTHENIAGeneral disorders29/20822/172
IRRITABILITYGeneral disorders15/20821/172
DYSPNOEARespiratory, thoracic and mediastinal disorders12/20821/172

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 WeeksTotal
Mean57.1 ± 7.0156.5 ± 7.8756.8 ± 7.41
Sex: Female, Male
Sex: Female, Male(Participants)ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 WeeksABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 WeeksTotal
Female6251113
Male146121267
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11. PubMed 24725237 ↗
  • Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver Int. 2018 Sep;38(9):1571-1575. doi: 10.1111/liv.13708. Epub 2018 Mar 14. PubMed 29377566 ↗
  • Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, Shiffman ML, Fried MW, Lovell S, Trinh R, Lopez-Talavera JC, Everson G. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver Int. 2015 Nov;35(11):2358-62. doi: 10.1111/liv.12931. Epub 2015 Sep 6. PubMed 26248955 ↗

Related links

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jan 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2012
First posted
Oct 11, 2012
Start
Oct 2012
Primary completionActual
Jan 2014
CompletionActual
Sep 2014
Results first posted
Jan 6, 2015
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01704755
Responsible party
Sponsor
First posted
Oct 11, 2012
Start date
Oct 2012
Primary completion
Jan 2014
Completion
Sep 2014
Results posted
Jan 6, 2015
Last update
Jul 12, 2021

Study contacts

Roger Trinh, MD
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir · Ribavirin

Start the discussion